# Endovia Health Sciences, Inc.: financial statements, quarterly

EDVA · NYSE · CIK 1553788 · [Consumer staples](/sectors/consumer-staples.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/edva.md) · [Financials](/companies/edva/financials.md) · [Filings](/companies/edva/filings.md) · [Insiders](/companies/edva/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/edva/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | [5,144](/filings/0001731122-24-001822.md) | [2,688 d](/filings/0001731122-25-000964.md) | [1,541](/filings/0001731122-25-000967.md) | [1,047](/filings/0001731122-25-001134.md) | [982](/filings/0001731122-25-001571.md) | [(2,768) d](/filings/0001731122-26-000577.md) | [68.6](/filings/0001731122-26-000769.md) | [(23.4) d](/filings/0001731122-26-001102.md) | [393 d](/filings/0001731122-25-001571.md) | [(365) d](/filings/0001731122-26-000577.md) | [4.2](/filings/0001731122-26-000769.md) | [0.0 d](/filings/0001731122-26-001102.md) |
| Cost of revenue | $k | [3,847](/filings/0001731122-24-001822.md) | [1,955 d](/filings/0001731122-25-000964.md) | [1,377](/filings/0001731122-25-000967.md) | [802](/filings/0001731122-25-001134.md) | [691](/filings/0001731122-25-001571.md) | [930 d](/filings/0001731122-25-000964.md) | [469](/filings/0001731122-25-000967.md) | [0.0 d](/filings/0001731122-25-001134.md) | [0.0 d](/filings/0001731122-25-001571.md) | not reported | not reported | not reported |
| Gross profit | $k | [1,297](/filings/0001731122-24-001822.md) | [733 d](/filings/0001731122-25-000964.md) | [164](/filings/0001731122-25-000967.md) | [244](/filings/0001731122-25-001134.md) | [291](/filings/0001731122-25-001571.md) | [(819) d](/filings/0001731122-26-000577.md) | [25.5](/filings/0001731122-26-000769.md) | [(32.1) d](/filings/0001731122-26-001102.md) | [(23.8) d](/filings/0001731122-25-001571.md) | [47.3 d](/filings/0001731122-26-000577.md) | [1.8](/filings/0001731122-26-000769.md) | [0.0 d](/filings/0001731122-26-001102.md) |
| Selling, general and administrative | $k | [3,049](/filings/0001731122-23-002111.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating income | $k | [(4,324)](/filings/0001731122-24-001822.md) | [(3,287) d](/filings/0001731122-25-000964.md) | [(3,250)](/filings/0001731122-25-000967.md) | [(3,691)](/filings/0001731122-25-001134.md) | [(2,670)](/filings/0001731122-25-001571.md) | [(290) d](/filings/0001731122-26-000577.md) | [(1,658)](/filings/0001731122-26-000769.md) | [(1,502)](/filings/0001731122-26-001102.md) | [(9,545)](/filings/0001731122-25-001571.md) | [(976) d](/filings/0001731122-26-000577.md) | [(979)](/filings/0001731122-26-000769.md) | [(2,007)](/filings/0001731122-26-001102.md) |
| Interest expense | $k | [221](/filings/0001731122-23-002111.md) | [1,296 d](/filings/0001731122-25-000964.md) | [533](/filings/0001731122-25-000967.md) | [622](/filings/0001731122-25-001134.md) | [890](/filings/0001731122-25-001571.md) | [1,657 d](/filings/0001731122-26-000577.md) | [637](/filings/0001731122-26-000769.md) | [625](/filings/0001731122-26-001102.md) | [320](/filings/0001731122-25-001571.md) | [941 d](/filings/0001731122-26-000577.md) | [889](/filings/0001731122-26-000769.md) | [231](/filings/0001731122-26-001102.md) |
| Income tax | $k | [0.0](/filings/0001731122-24-001822.md) | [0.0 d](/filings/0001731122-25-000964.md) | [0.0](/filings/0001731122-25-000967.md) | [0.0](/filings/0001731122-25-001134.md) | [0.0](/filings/0001731122-25-001571.md) | [0.0 d](/filings/0001731122-26-000577.md) | [0.0](/filings/0001731122-26-000769.md) | [0.0](/filings/0001731122-26-001102.md) | [0.0](/filings/0001731122-25-001571.md) | [0.0 d](/filings/0001731122-26-000577.md) | [0.0](/filings/0001731122-26-000769.md) | [0.0](/filings/0001731122-26-001102.md) |
| Net income | $k | [(5,670)](/filings/0001731122-24-001822.md) | [(5,994) d](/filings/0001731122-25-000964.md) | [(4,671)](/filings/0001731122-25-001571.md) | [(5,327)](/filings/0001731122-25-001571.md) | [(4,720)](/filings/0001731122-25-001571.md) | [(9,039) d](/filings/0001731122-26-000577.md) | [(3,650)](/filings/0001731122-26-001102.md) | [(8,493)](/filings/0001731122-26-001102.md) | [(9,886)](/filings/0001731122-25-001571.md) | [(3,205) d](/filings/0001731122-26-000577.md) | [(2,136)](/filings/0001731122-26-001102.md) | [(2,055)](/filings/0001731122-26-001102.md) |
| Diluted EPS | $ per share | [(0.13)](/filings/0001731122-23-002111.md) | not reported | not reported | not reported | not reported | not reported | [(1.97)](/filings/0001731122-26-000769.md) | not reported | not reported | not reported | [(0.47)](/filings/0001731122-26-000769.md) | not reported |
| Basic EPS | $ per share | [(0.13)](/filings/0001731122-23-002111.md) | not reported | not reported | not reported | not reported | not reported | [(1.97)](/filings/0001731122-26-000769.md) | not reported | not reported | not reported | [(0.47)](/filings/0001731122-26-000769.md) | not reported |

- Revenue: us-gaap:Revenues
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [0.1](/filings/0001731122-23-002111.md) | [0.4](/filings/0001731122-25-000964.md) | [0.0](/filings/0001731122-24-000818.md) | not reported | not reported | [0.0](/filings/0001731122-26-000577.md) | not reported | [0.0](/filings/0001731122-25-001134.md) | [0.3](/filings/0001731122-25-001571.md) | [0.3](/filings/0001731122-26-001102.md) | [0.4](/filings/0001731122-26-000769.md) | [0.2](/filings/0001731122-26-001102.md) |
| Current assets | $m | [5.1](/filings/0001731122-23-002111.md) | [4.0](/filings/0001731122-25-000964.md) | [2.8](/filings/0001731122-24-000818.md) | [2.5](/filings/0001731122-24-001253.md) | [3.0](/filings/0001731122-24-001822.md) | [1.9](/filings/0001731122-26-000577.md) | [1.7](/filings/0001731122-25-000967.md) | [1.6](/filings/0001731122-25-001134.md) | [2.0](/filings/0001731122-25-001571.md) | [0.6](/filings/0001731122-26-001102.md) | [0.7](/filings/0001731122-26-000769.md) | [0.9](/filings/0001731122-26-001102.md) |
| Total assets | $m | [11.2](/filings/0001731122-23-002111.md) | [9.9](/filings/0001731122-25-000964.md) | [8.6](/filings/0001731122-24-000818.md) | [8.1](/filings/0001731122-24-001253.md) | [8.4](/filings/0001731122-24-001822.md) | [2.8](/filings/0001731122-26-000577.md) | [2.5](/filings/0001731122-25-000967.md) | [22.2](/filings/0001731122-25-001134.md) | [22.5](/filings/0001731122-25-001571.md) | [1.0](/filings/0001731122-26-001102.md) | [0.8](/filings/0001731122-26-000769.md) | [1.1](/filings/0001731122-26-001102.md) |
| Current liabilities | $m | [11.1](/filings/0001731122-23-002111.md) | [14.8](/filings/0001731122-25-000964.md) | [17.0](/filings/0001731122-24-000818.md) | [16.8](/filings/0001731122-24-001253.md) | [17.8](/filings/0001731122-24-001822.md) | [19.4](/filings/0001731122-26-000577.md) | [20.4](/filings/0001731122-25-000967.md) | [13.4](/filings/0001731122-25-001134.md) | [15.6](/filings/0001731122-25-001571.md) | [16.3](/filings/0001731122-26-001102.md) | [17.0](/filings/0001731122-26-000769.md) | [16.8](/filings/0001731122-26-001102.md) |
| Total liabilities | $m | [11.9](/filings/0001731122-23-002111.md) | [15.5](/filings/0001731122-25-000964.md) | [18.1](/filings/0001731122-24-000818.md) | [18.4](/filings/0001731122-24-001253.md) | [19.2](/filings/0001731122-24-001822.md) | [21.4](/filings/0001731122-26-000577.md) | [22.5](/filings/0001731122-25-000967.md) | [13.5](/filings/0001731122-25-001134.md) | [15.7](/filings/0001731122-25-001571.md) | [16.3](/filings/0001731122-26-001102.md) | [17.0](/filings/0001731122-26-000769.md) | [16.8](/filings/0001731122-26-001102.md) |
| Long-term debt | $m | [0.4](/filings/0001731122-23-002111.md) | [0.5](/filings/0001731122-25-000964.md) | [0.8](/filings/0001731122-24-000818.md) | [1.4](/filings/0001731122-24-001253.md) | [1.3](/filings/0001731122-24-001822.md) | [2.0](/filings/0001731122-26-000577.md) | [2.1](/filings/0001731122-25-000967.md) | [0.1](/filings/0001731122-25-001134.md) | [0.1](/filings/0001731122-25-001571.md) | [0.0](/filings/0001731122-26-001102.md) | [0.0](/filings/0001731122-26-000769.md) | not reported |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Short-term borrowings | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [(0.7)](/filings/0001731122-24-001822.md) | [(5.6)](/filings/0001731122-26-000577.md) | [(9.5)](/filings/0001731122-25-001571.md) | [(10.4)](/filings/0001731122-25-001571.md) | [(10.8)](/filings/0001731122-25-001571.md) | [(18.6)](/filings/0001731122-26-000769.md) | [(20.0)](/filings/0001731122-26-000769.md) | [8.7](/filings/0001731122-25-001571.md) | [6.8](/filings/0001731122-25-001571.md) | [(15.3)](/filings/0001731122-26-001102.md) | [(16.2)](/filings/0001731122-26-000769.md) | [(15.7)](/filings/0001731122-26-001102.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Current portion of debt: not reported
- Short-term borrowings: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(1,982) d](/filings/0001731122-24-001822.md) | [(1,685) d](/filings/0001731122-25-000964.md) | [(1,308)](/filings/0001731122-25-000967.md) | [(2,430) d](/filings/0001731122-25-001134.md) | [(2,645) d](/filings/0001731122-25-001571.md) | [(920) d](/filings/0001731122-26-000577.md) | [(808)](/filings/0001731122-26-000769.md) | [(551) d](/filings/0001731122-26-001102.md) | [(2,470) d](/filings/0001731122-25-001571.md) | [(991) d](/filings/0001731122-26-000577.md) | [(930)](/filings/0001731122-26-000769.md) | [(1,092) d](/filings/0001731122-26-001102.md) |
| Capital expenditure | $k | [0.0 d](/filings/0001731122-23-002111.md) | [1.5 d](/filings/0001731122-25-000964.md) | [0.0](/filings/0001731122-24-000818.md) | not reported | not reported | [0.0 d](/filings/0001731122-25-000964.md) | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [37.4](/filings/0001731122-23-002111.md) | [37.4](/filings/0001731122-24-000818.md) | [42.1](/filings/0001731122-24-001253.md) | [42.8](/filings/0001731122-24-001822.md) | [1.1](/filings/0001731122-25-000967.md) | [1.2](/filings/0001731122-25-001134.md) | [1.3](/filings/0001731122-25-001571.md) | [1.9](/filings/0001731122-26-000769.md) | [0.5](/filings/0001731122-26-001102.md) | [2.2](/filings/0001731122-25-001571.md) | [4.6](/filings/0001731122-26-000769.md) | [3.1](/filings/0001731122-26-001102.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 6,412,521 at 2026-08-19, from the cover of the [10-Q filed 2026-08-19](/filings/0001731122-26-001102.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:42 ET. No prices; not investment advice.